透析患者碳酸镧与司维拉姆心血管结局比较
该研究采用目标试验模拟方法,基于中国肾脏数据系统,比较透析合并高磷血症且无既往主要不良心血管事件(MACE)患者启动碳酸镧或司维拉姆后的心血管结局。经倾向评分1:1匹配后,碳酸镧组MACE风险显著低于司维拉姆组(HR 0.79,95%CI 0.68-0.92),全因死亡和心血管死亡风险亦较低。
要点
- 碳酸镧较司维拉姆降低透析患者MACE风险(HR 0.79)。
- 碳酸镧组全因死亡和心血管死亡风险均更低。
- 绝对风险降低2.68%,需治疗人数为37。
核心结论
- 在透析合并高磷血症且无既往MACE患者中,启动碳酸镧较司维拉姆与更低的心血管事件和死亡风险相关。
研究设计与样本
- 采用目标试验模拟方法,基于中国肾脏数据系统数据,比较碳酸镧与司维拉姆启动的透析患者。
- 采用活性对照、新用户设计,经倾向评分1:1匹配,共纳入10,518例匹配患者(每组5,259例)。
主要发现
- 3年内司维拉姆组发生325例MACE,碳酸镧组发生280例,累积发生率分别为12.2%和9.5%。
- 碳酸镧组MACE风险显著低于司维拉姆组(HR 0.79;95%CI 0.68-0.92),绝对风险降低2.68%,需治疗人数37。
- 碳酸镧组全因死亡风险(HR 0.83;95%CI 0.75-0.93)和心血管死亡风险(HR 0.72;95%CI 0.59-0.88)均更低。
- 敏感性和亚组分析结果一致,竞争风险分析中MACE风险降低仍显著。
临床怎么用
- 对于透析合并高磷血症且无既往MACE的患者,选择碳酸镧而非司维拉姆可能带来更优的心血管获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyperphosphatemia is a key component of chronic kidney disease-mineral and bone disorder and is associated with cardiovascular morbidity and mortality in patients receiving dialysis. Non-calcium-based phosphate binders, including sevelamer and lanthanum carbonate, are widely used, yet comparative evidence on clinical outcomes remains limited. METHODS: We emulated a target trial using data from the China Renal Data System to compare lanthanum carbonate versus sevelamer initiation among patients receiving dialysis with hyperphosphatemia and no documented prior major adverse cardiovascular events (MACE). Using an active-comparator, new-user design, patients were matched 1:1 by propensity scores. The primary outcome was incident MACE, defined as a composite of myocardial infarction, stroke, or cardiovascular death. Secondary outcomes included all-cause and cardiovascular mortality. Cox proportional hazards models were used to estimate hazard ratios (HRs), and cumulative incidence was estimated using the Kaplan-Meier method. RESULTS: Among 10,518 matched patients (5,259 per group), 325 MACE events occurred in the sevelamer group and 280 in the lanthanum carbonate group over 3 years. The cumulative incidence of MACE was 12.2% versus 9.5%, respectively. Lanthanum carbonate initiation was associated with a lower risk of MACE (HR, 0.79; 95% CI, 0.68 to 0.92), corresponding to an absolute risk reduction of 2.68% and a number needed to treat of 37. Lanthanum carbonate was also associated with lower risks of all-cause mortality (HR, 0.83; 95% CI, 0.75 to 0.93) and cardiovascular mortality (HR, 0.72; 95% CI, 0.59 to 0.88). Results were consistent across sensitivity and subgroup analyses. In competing-risk analyses, the association with lower MACE risk remained significant. CONCLUSIONS: In this target trial emulation, initiation of lanthanum carbonate was associated with lower risks of cardiovascular events and mortality compared with sevelamer among patients receiving dialysis with hyperphosphatemia and no documented prior MACE.
引用
- Liu J, Jin L, Luo F, et al. Comparative Cardiovascular Outcomes of Lanthanum Carbonate and Sevelamer in Dialysis. J Am Soc Nephrol. 2026. PMID: 42837171. doi:10.1681/ASN.0000001289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。